L Makepeace1, M Scoggins1, B Mitrea1, Y Li2, A Edwards1, C L Tinkle3, S Hwang1, A Gajjar4, Z Patay5. 1. From the Departments of Diagnostic Imaging (L.M., M.S., B.M., A.E., S.H., Z.P.). 2. Biostatistics (Y.L.). 3. Radiation Oncology (C.L.T.). 4. Oncology (A.G.), St. Jude Children's Research Hospital, Memphis, Tennessee. 5. From the Departments of Diagnostic Imaging (L.M., M.S., B.M., A.E., S.H., Z.P.) Zoltan.Patay@STJUDE.ORG.
Abstract
BACKGROUND AND PURPOSE: Diffuse intrinsic pontine glioma is a devastating childhood cancer that despite being primarily diagnosed by MR imaging alone, lacks robust prognostic imaging features. This study investigated patterns and quantification of extrapontine lesion extensions as potential prognostic imaging biomarkers for survival in children with newly diagnosed diffuse intrinsic pontine glioma. MATERIALS AND METHODS: Volumetric analysis of baseline MR imaging studies was completed in 131 patients with radiographically defined typical diffuse intrinsic pontine gliomas. Extrapontine tumor extension was classified according to the direction of extension: midbrain, medulla oblongata, and right and left middle cerebellar peduncles; various extrapontine lesion extension patterns were evaluated. The Kaplan-Meier method was used to estimate survival differences; linear regression was used to evaluate clinical-radiographic variables prognostic of survival. RESULTS: At least 1 extrapontine lesion extension was observed in 125 patients (95.4%). Of the 11 different extrapontine lesion extension patterns encountered in our cohort, 2 were statistically significant predictors of survival. Any extension into the middle cerebellar peduncles was prognostic of shorter overall survival (P = .01), but extension into both the midbrain and medulla oblongata but without extension into either middle cerebellar peduncle was prognostic of longer overall survival compared with those having no extension (P = .04) or those having any other pattern of extension (P < .001). CONCLUSIONS: Within this large cohort of patients with typical diffuse intrinsic pontine gliomas, 2 specific extrapontine lesion extension patterns were associated with a significant overall survival advantage or disadvantage. Our findings may be valuable for risk stratification and radiation therapy planning in future clinical trials.
BACKGROUND AND PURPOSE: Diffuse intrinsic pontine glioma is a devastating childhood cancer that despite being primarily diagnosed by MR imaging alone, lacks robust prognostic imaging features. This study investigated patterns and quantification of extrapontine lesion extensions as potential prognostic imaging biomarkers for survival in children with newly diagnosed diffuse intrinsic pontine glioma. MATERIALS AND METHODS: Volumetric analysis of baseline MR imaging studies was completed in 131 patients with radiographically defined typical diffuse intrinsic pontine gliomas. Extrapontine tumor extension was classified according to the direction of extension: midbrain, medulla oblongata, and right and left middle cerebellar peduncles; various extrapontine lesion extension patterns were evaluated. The Kaplan-Meier method was used to estimate survival differences; linear regression was used to evaluate clinical-radiographic variables prognostic of survival. RESULTS: At least 1 extrapontine lesion extension was observed in 125 patients (95.4%). Of the 11 different extrapontine lesion extension patterns encountered in our cohort, 2 were statistically significant predictors of survival. Any extension into the middle cerebellar peduncles was prognostic of shorter overall survival (P = .01), but extension into both the midbrain and medulla oblongata but without extension into either middle cerebellar peduncle was prognostic of longer overall survival compared with those having no extension (P = .04) or those having any other pattern of extension (P < .001). CONCLUSIONS: Within this large cohort of patients with typical diffuse intrinsic pontine gliomas, 2 specific extrapontine lesion extension patterns were associated with a significant overall survival advantage or disadvantage. Our findings may be valuable for risk stratification and radiation therapy planning in future clinical trials.
Authors: Marc H Jansen; Sophie E Veldhuijzen van Zanten; Esther Sanchez Aliaga; Martijn W Heymans; Monika Warmuth-Metz; Darren Hargrave; Erica J van der Hoeven; Corrie E Gidding; Eveline S de Bont; Omid S Eshghi; Roel Reddingius; Cacha M Peeters; Antoinette Y N Schouten-van Meeteren; Rob H J Gooskens; Bernd Granzen; Gabriel M Paardekooper; Geert O Janssens; David P Noske; Frederik Barkhof; Christof M Kramm; W Peter Vandertop; Gertjan J Kaspers; Dannis G van Vuurden Journal: Neuro Oncol Date: 2014-06-05 Impact factor: 12.300
Authors: Tina Young Poussaint; Mehmet Kocak; Sridhar Vajapeyam; Roger I Packer; Richard L Robertson; Russell Geyer; Daphne Haas-Kogan; Ian F Pollack; Gilbert Vezina; Robert Zimmerman; Soonmee Cha; Zoltan Patay; James M Boyett; Larry E Kun Journal: Neuro Oncol Date: 2011-02-04 Impact factor: 12.300
Authors: Daphne A Haas-Kogan; Anuradha Banerjee; Mehmet Kocak; Michael D Prados; J Russell Geyer; Maryam Fouladi; Tracy McKnight; Tina Young Poussaint; Alberto Broniscer; Susan M Blaney; James M Boyett; Larry E Kun Journal: Neuro Oncol Date: 2008-04-16 Impact factor: 12.300
Authors: Ashley E Conway; Wilburn E Reddick; Yimei Li; Ying Yuan; John O Glass; Justin N Baker; Larry E Kun; Alberto Broniscer; Zoltan Patay Journal: Neuroradiology Date: 2014-03-14 Impact factor: 2.804
Authors: Alberto Broniscer; Justin N Baker; Michael Tagen; Arzu Onar-Thomas; Richard J Gilbertson; Andrew M Davidoff; Atmaram S Pai Panandiker; Atmaram Pai Panandiker; Wing Leung; Thomas K Chin; Clinton F Stewart; Mehmet Kocak; Christopher Rowland; Thomas E Merchant; Sue C Kaste; Amar Gajjar Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Lindsey M Hoffman; Sophie E M Veldhuijzen van Zanten; Niclas Colditz; Joshua Baugh; Brooklyn Chaney; Marion Hoffmann; Adam Lane; Christine Fuller; Lili Miles; Cynthia Hawkins; Ute Bartels; Eric Bouffet; Stewart Goldman; Sarah Leary; Nicholas K Foreman; Roger Packer; Katherine E Warren; Alberto Broniscer; Mark W Kieran; Jane Minturn; Melanie Comito; Emmett Broxson; Chie-Schin Shih; Soumen Khatua; Murali Chintagumpala; Anne Sophie Carret; Nancy Yanez Escorza; Timothy Hassall; David S Ziegler; Nicholas Gottardo; Hetal Dholaria; Renee Doughman; Martin Benesch; Rachid Drissi; Javad Nazarian; Nada Jabado; Nathalie Boddaert; Pascale Varlet; Géraldine Giraud; David Castel; Stephanie Puget; Chris Jones; Esther Hulleman; Piergiorgio Modena; Marzia Giagnacovo; Manila Antonelli; Torsten Pietsch; Gerrit H Gielen; David T W Jones; Dominik Sturm; Stefan M Pfister; Nicolas U Gerber; Michael A Grotzer; Elke Pfaff; André O von Bueren; Darren Hargrave; Guirish A Solanki; Filip Jadrijevic Cvrlje; Gertjan J L Kaspers; William P Vandertop; Jacques Grill; Simon Bailey; Veronica Biassoni; Maura Massimino; Raphaël Calmon; Esther Sanchez; Brigitte Bison; Monika Warmuth-Metz; James Leach; Blaise Jones; Dannis G van Vuurden; Christof M Kramm; Maryam Fouladi Journal: J Clin Oncol Date: 2018-05-10 Impact factor: 44.544
Authors: Alberto Broniscer; Sharyn D Baker; Cynthia Wetmore; Atmaram S Pai Panandiker; Jie Huang; Andrew M Davidoff; Arzu Onar-Thomas; John C Panetta; Thomas K Chin; Thomas E Merchant; Justin N Baker; Sue C Kaste; Amar Gajjar; Clinton F Stewart Journal: Clin Cancer Res Date: 2013-03-27 Impact factor: 12.531
Authors: James L Leach; James Roebker; Austin Schafer; Joshua Baugh; Brooklyn Chaney; Christine Fuller; Maryam Fouladi; Adam Lane; Renee Doughman; Rachid Drissi; Mariko DeWire-Schottmiller; David S Ziegler; Jane E Minturn; Jordan R Hansford; Stacie S Wang; Michelle Monje-Deisseroth; Paul G Fisher; Nicholas G Gottardo; Hetal Dholaria; Roger Packer; Katherine Warren; Sarah E S Leary; Stewart Goldman; Ute Bartels; Cynthia Hawkins; Blaise V Jones Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300